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Abstract
Background: Human Papillomavirus (HPV) genotyping has an increasingly important role in cervical cancer screening
and vaccination monitoring, however, without an internationally agreed standard reference assay. The test results from
the most widely used genotyping assays are read manually and hence prone to inter-observer variability. The reading
of test results on the CLART HPV2 genotyping assay is, on the other hand, automated. The aim of our study was to
directly compare the detection of HPV genotypes and high-grade cervical intraepithelial neoplasia (CIN) by CLART,
Linear Array (LA), and Hybrid Capture 2 (HC2) using samples stored in SurePath.
Methods: Residual material from 401 routine samples from women with abnormal cytology was tested by CLART,
LA, and HC2 (ClinicalTrial.gov: NCT01671462, Ethical Committee approval: H-2012-070). Histological outcomes were
ascertained by linkage to the Danish nation-wide Pathology Data Bank. For comparison of CLART and LA in terms of
genotype detection, we calculated κ-coefficients, and proportions of overall and positive agreement. For comparison of
CIN detection between CLART, LA, and HC2, we calculated the relative sensitivity and specificity for high-grade CIN.
Results: The κ-coefficient for agreement in detection of genotypes 16, 18, 31, 33, 35, and 51 was ≥0.90 (overall
agreement: 98-99%, positive agreement: 84-95%). The values were slightly lower, but still in the “substantial” range
for genotypes 39, 45, 52, 56, 58, 59, and several low-risk genotypes. The relative sensitivity of CLART for≥ CIN2 and≥ CIN3
was not significantly lower than that of LA and HC2, although CLART showed a higher specificity than HC2.
Conclusions: In Danish women with abnormal SurePath cytology, CLART and LA were highly comparable for detection
of most high-risk and low-risk genotypes; and CLART’s sensitivity for high-grade CIN was comparable to that of both LA
and HC2.
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Background
Cervical cancer is caused by high-risk Human Papillo-
mavirus (HPV) genotypes, whereas low-risk genotypes
cause benign lesions [1-3]. Genotyping of HPV infec-
tions has an increasing role in cervical screening and
vaccination monitoring [4,5], however, without an inter-
nationally agreed standard reference HPV genotyping
assay [4]. With more than 100 genotyping assays on the
market, the question remains: which genotyping assays
have the requisite validation data to support their use.
The two most widely used, Linear Array (LA; Roche
Diagnostics, Pleasanton, CA), and INNO-LiPA (Fujirebio
Europe, Ghent, Belgium), detect 37 and 28 genotypes,
respectively, and are typically read manually and hence
prone to inter-observer variability in reporting test
results. Papillocheck (Greiner Bio-One, Frickenhausen,
Gemany), on the other hand, detects 24 genotypes, and
uses automated reading [6-8]. In contrast to these commer-
cially available genotyping assays, the GP5+/6+ polymerase
chain reaction (PCR) followed by enzyme immunoassay is
an in-house assay and its performance may be laboratory-
dependent.
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CLART HPV2 (CLART; Genomica, Madrid, Spain) is a
commercially available PCR-based genotyping HPV DNA
assay, based on genotype amplicon-specific hybridization
on a microarray. The assay has two internal controls, a
DNA control (human CTFR gene) for sample sufficiency,
and an amplification control (plasmid) for process control
in each tube. It detects 35 genotypes: the 13 high-risk (16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) [1] and 22
low-risk (6, 11, 26, 40, 42, 43, 44, 53, 54, 61, 62, 66, 70, 71,
72, 73, 81, 82, 83, 84, 85, 89). Detection of individual ge-
notypes was calibrated against known copies of cloned
plasmids. Essential for high-throughput screening set-
tings, the reading of test results is automated. Further-
more, CLART can be applied to several sample types,
including formalin-fixed paraffin-embedded specimens
[9,10]. Several laboratories participated with CLART in
the WHO HPV LabNet Proficiency Studies [4,11], em-
phasizing that while it is rarely described in scientific
publications [12-15], it is frequently used in clinical,
non-research laboratories.
Here, we compared the analytical and clinical charac-
teristics of CLART to those of LA and Hybrid Capture 2
(HC2; Qiagen, Gaithersburg, MD) in Danish women
with abnormal cytology.
Methods
The data presented in this study were partially collected
within the Danish arm of a European CE-IVD trial
evaluating a new molecular HPV assay (ClinicalTrials.
Gov ID: NCT01671462). From this trial, test results on
HC2 and LA were used here, whereas the CLART HPV2
testing was undertaken specifically for the purpose of the
current study. Residual material from 411 consecutive,
unselected SurePath samples with abnormal cytology
(atypical squamous cells of undetermined significance or
worse, ≥ASCUS) were collected from up to 10 routine
racks per day processed in the laboratory between
September and October 2012. After the samples had
been collected, we excluded those with insufficient
quantity, ≤1.0 ml, of the residual SurePath material
available post the routine cytology. Of the collected
samples, 10 were excluded due to this criterion.
Cytology evaluation was undertaken by Focal Point
assisted screening (BD, Burlington, NC). Slides were
read by cytoscreeners, with abnormal findings adjudi-
cated by pathologists and reported using the Bethesda
2001 system. Women aged ≥30 years with ASCUS had
routine reflex HC2 HPV triage. After a negative HC2
test result, any initial ASCUS diagnoses were routinely
downgraded to normal cytology, with women being re-
ferred back to routine screening. Other cytology reading
was undertaken blinded to HPV testing. Women with
HC2-positive ASCUS were referred for colposcopy, as
were women with high-grade squamous intraepithelial
lesions (HSIL), atypical squamous cells – cannot exclude
HSIL (ASC-H), atypical glandular cells (AGC), adenocar-
cinoma in situ (AIS), cytological squamous carcinoma,
and women with persistent ASCUS at age <30 years or
low-grade squamous intraepithelial lesions (LSIL). Women
with ASCUS at age <30 years or LSIL had repeated cyto-
logical testing. Follow-up tests until end of February 2014
were retrieved from the Danish National Pathology Data
Bank (Patobank; [16]). Cases of cervical cancer were
adjudicated, based on the free text in the Patobank, by
an expert pathologist from the same laboratory.
HPV testing
One-half ml of SurePath sample material was centrifuged
for five minutes at 14,000 revolutions per minute. Cell pel-
lets were re-suspended in a mix of 180 μl phosphate buff-
ered saline (10× conc. pH 7.4, Pharmacy product) and 20 μl
Proteinase K (Roche Diagnostics, Rotkreuz, Switzerland).
Samples were vortexed and incubated for one hour at 56°C
and one hour at 90°C. DNA was purified using MagNa
Pure LC 96 instrument with MagNa Pure LC Total Nucleic
Acid Isolation Kit (Roche Diagnostics). Aliquots of ex-
tracted DNA were used for both CLART and LA testing.
On average, samples were DNA extracted 17 days (range
10–27) after having been received in the laboratory. Ex-
tracted DNA was stored frozen until LA and CLART
testing.
PCR amplification was performed using CLART HPV2
Amplification kit (Genomica). Five μl of purified DNA
were used as template per reaction. Prior to visualization,
the PCR products were denatured at 95°C for 10 minutes.
Hybridization was performed using 10 μl of the denatured
PCR products on the CLART microarray, and subsequent
visualization was done according to manufacturer’s
specifications. The genotyping results were analyzed
and reported automatically on the Clinical Array Reader
(Genomica).
LA detects the 13 high-risk, and 24 low-risk geno-
types. The assay has an internal human β-globin control
for sample sufficiency and assay performance. With the
final volume of 50 μl, 12.5 μl of purified sample DNA
and 4 μl of purified control DNA were added for each
sample and control PCR reaction. PCR was performed
on GeneAmp PCR system 9700 (Applied Biosystems,
Foster City, CA). Twenty-five μl of PCR reaction were
used for LA testing according to the manufacturer’s
protocol. The results on the LA strips were read inde-
pendently by DME and a scientific assistant. In case of
disagreement, consensus was sought. The difference in
the DNA input per test between LA and CLART reflects
the manufacturer specifications.
HC2 analysis was undertaken on the SurePath post-
quot material, in concordance with the manufacturer’s
specifications. Samples were denatured manually prior
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to the analysis on the manual HC2 Modular system
(Qiagen, Gaithersburg, MD, USA). On average, samples
were denatured 17 (range: 3–23) days after having been
received in the laboratory and stored according to the
manufacturer’s recommendations prior to HC2 testing.
Statistical analyses
A sample was considered high-risk positive for HPV if at
least one high-risk genotype was detected, and low-risk
positive when at least one of the remaining 18 genotypes
detectable by both assays (6, 11, 26, 40, 42, 53, 54, 61,
62, 66, 70, 71, 72, 73, 81, 82, 83, 84) was detected with-
out any high-risk genotype. CLART automatically re-
ports genotypes separately when they are detected in an
“uncertainty” range, i.e. with weak signals. Reflecting
routine practice in our facility, these genotypes are con-
sidered positive only if part of multiple infections. The
same definition was used for LA in case of bands with
weak signal intensity. A positive HC2 test result was
defined as RLU/CO value ≥1.0.
Differences in the distribution of women’s characteris-
tics for the three assays were calculated using the Χ2 dis-
tribution. For all 31 HPV genotypes detectable by both
assays, we calculated the κ-coefficients and proportions
of overall and positive agreement. κ-coefficients >0.60
were considered to indicate “substantial” agreement [17].
Overall agreement was calculated as the proportion of
all samples that returned the same test result on both
CLART and LA (no genotype, or same genotype). Positive
agreement was calculated as conditional probability that
both assays detected a particular genotype if at least one
did. The proportion of high-grade CIN (≥CIN2 or ≥CIN3)
with a positive test result on a particular HPV assay was
used as an indicator of the assay’s clinical sensitivity. As an
indicator of clinical specificity, we calculated the propor-
tion of women testing negative among those without high-
grade CIN; we assumed that women with cytology but
without histology in follow-up had no high-grade CIN,
and excluded women who were lost to follow-up. The 95%
confidence intervals (CI) for sensitivity and specificity were
calculated using binomial distribution. We calculated the
relative clinical sensitivity and specificity for CLART by
comparing its sensitivity and specificity to LA and HC2.
The 95% CI for relative sensitivity and specificity, and for
the relative prevalence (RP) of genotypes (CLART vs. LA),
were calculated assuming that their logarithms were ap-
proximately normally distributed.
Ethical approval
LA and HC2 data were collected with informed consent
as part of the Danish arm of a multicenter European trial
(ClinicalTrial.gov Identifier: NCT01671462), approved by
the Danish Capital Region Ethical Committee (H-2012-
070). Informed consent was obtained by the sample taking
gynecologists, and maintained in the women’s patient re-
cords, as well as in copy at the Department of Pathology
in concordance with Danish Ethical guidelines. Additional
testing on CLART, not used for clinical management, was
undertaken as a quality development study, for which
ethical approval and informed consent are not required, in
concordance with the current Danish law.
Results
The 401 women were aged 17–78 years (mean 32.8, me-
dian 29). Most (N = 357, 89%) were in the screening age
(23–65 years). ASCUS was diagnosed in 103 (26%)
women, 161 had LSIL (40%), 30 ASC-H (7%), 106 HSIL
(26%) and one (<1%) had cytological signs of carcinoma
(Table 1). On average, women were followed for 17 months
(range: 506–542 days). Seventeen (4%) were lost to follow-
up. On CLART and LA, the proportion of high-risk geno-
types decreased by age and increased by the severity of the
cytologic interpretation; on HC2, the trends were not sta-
tistically significant. The differences between CLART and
LA were not statistically significant. Between CLART and
HC2, some differences were seen, particularly by age
where more women aged ≥30 years had high-risk HPV
genotypes detected on HC2 than on CLART. The differ-
ences in the distribution of test results in women lost to
follow-up were not statistically significant.
Detection of HPV genotypes
In total, 311 (78%) women had high-risk genotypes on
CLART, and 326 on LA (81%; RP: 0.95, 95% CI: 0.89-
1.02). CLART detected statistically significantly fewer
HPV 39, 45, 54, 62, and 73 infections than LA, whereas
LA detected fewer HPV 58 and 82 (Table 2). For HPV
16, 18, 31, 33, 35, and 51, the agreement between
CLART and LA was excellent (κ ≥ 0.90, overall agree-
ment 98-99%, positive agreement 84-95%). For HPV 39,
45, 52, 56, 58, and 59, the agreement was substantial
(κ ≥ 0.60, overall agreement 94-96%, positive agreement
46-64%); however, for HPV 68, the agreement was poor
(κ = 0.26, overall agreement 93%, positive agreement
17%). For the 18 low-risk HPV genotypes detectable by
both genotyping assays the agreement was in general
good, although for genotypes HPV 54, 62, 73, and 82,
the agreement was poor (κ < 0.60, overall agreement 93-
96%, positive agreement 35-42%). However, these geno-
types and HPV 68 were not highly prevalent in this
population. This was similar in 125 women with ≥CIN2
(treatment threshold in Denmark), with CLART detect-
ing statistically significantly fewer HPV 45 infections
than LA, RP: 0.35 (95% CI: 0.14-0.87; Table 3). CLART
found single HPV infections in 130 (32%), and multiple
infections in 235 (59%) women (Table 4). For LA, this
was the case in 121 (30%) and 259 (65%), respectively.
These differences were not statistically significant, RP
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Table 1 Description of the 401 women included in the study

















CLART vs. LA CLART vs. HC2
Total 401 (100%) 311 (78%) 54 (13%) 36 (9%) 326 (81%) 54 (13%) 21 (5%) 355 (89%) 46 (11%)
Age (years)
<30 215 (100%) 180 (84%) 21 (10%) 14 (7%) 184 (86%) 21 (10%) 10 (5%) 192 (89%) 23 (11%) 0.701 0.090
30-39 96 (100%) 74 (77%) 16 (17%) 6 (6%) 80 (83%) 13 (14%) 3 (3%) 86 (90%) 10 (10%) 0.462 0.020
≥40 90 (100%) 57 (63%) 17 (19%) 16 (18%) 62 (69%) 20 (22%) 8 (9%) 77 (86%) 13 (14%) 0.210 0.001
P 0.001 0.012 0.602
Cytology
ASCUS 103 (100%) 78 (76%) 11 (11%) 14 (14%) 82 (80%) 10 (10%) 11 (11%) 88 (85%) 15 (15%) 0.776 0.078
LSIL 161 (100%) 113 (70%) 37 (23%) 11 (7%) 119 (74%) 38 (24%) 4 (2%) 140 (87%) 21 (13%) 0.180 <0.001
≥HSILa 137 (100%) 120 (88%) 6 (4%) 11 (8%) 125 (91%) 6 (4%) 6 (4%) 127 (93%) 10 (7%) 0.455 0.156
P <0.001 <0.001 0.156
Worst follow-up outcome
No follow-up 17 (100%) 14 (82%) 2 (12%) 1 (6%) 14 (82%) 3 (18%) 0 (0%) 16 (94%) 1 (6%) 0.549 0.287
Normal cytology or negative HPV test 75 (100%) 56 (75%) 8 (11%) 11 (15%) 60 (80%) 6 (8%) 9 (12%) 60 (80%) 15 (20%) 0.732 0.435
Abnormal cytology or positive HPV test 10 (100%) 7 (70%) 2 (20%) 1 (10%) 8 (80%) 2 (20%) 0 (0%) 8 (80%) 2 (20%) 0.587 0.605
Inadequate histology 9 (100%) 3 (33%) 3 (33%) 3 (33%) 3 (33%) 3 (33%) 3 (33%) 6 (67%) 3 (33%) 1.000 0.157
CIN0 98 (100%) 57 (58%) 29 (30%) 12 (12%) 61 (62%) 31 (32%) 6 (6%) 77 (79%) 21 (21%) 0.333 0.002
CIN1b 67 (100%) 58 (87%) 5 (7%) 4 (6%) 60 (90%) 5 (7%) 2 (3%) 65 (97%) 2 (3%) 0.704 0.028
CIN2 35 (100%) 32 (91%) 2 (6%) 1 (3%) 33 (94%) 2 (6%) 0 (0%) 34 (97%) 1 (3%) 0.602 0.303
CIN3 86 (100%) 81 (94%) 3 (3%) 2 (2%) 83 (97%) 2 (2%) 1 (1%) 85 (99%) 1 (1%) 0.757 0.096
Cervical cancer 4 (100%) 3 (75%) 0 (0%) 1 (25%) 4 (100%) 0 (0%) 0 (0%) 4 (100%) 0 (0%) 0.285 0.285
P <0.001 <0.001 <0.001
Abbreviations: ASCUS atypical squamous cells of undetermined significance, CIN cervical intraepithelial neoplasia, HPV human papillomavirus, HSIL high-grade squamous intraepithelial lesions, LSIL low-grade squamous
intraepithelial lesions.
aIncluding atypical squamous cells – cannot exclude HSIL, adenocarcinoma in situ, atypical glandular cells, cytological signs of carcinoma.
bIncluding histological atypia and CIN not otherwise specified.











for single infections: 1.07 (95% CI: 0.87-1.32). The κ was
0.64, with an overall agreement of 81% (95% CI: 77–85).
For detecting high- and low-risk infections (Table 5), the
κ was 0.76, with an overall agreement of 92% (95% CI:
88–94), and positive agreement (for detecting at least
one high-risk genotype) of 92% (95% CI: 89–95). The
differences in detecting high-risk infections overall (for
detecting at least one high-risk genotype) were not sig-
nificant, RP: 0.95 (95% CI: 0.89-1.02).
The agreement with HC2 in detecting high-risk HPV
infections was lower for both genotyping assays (Table 6):
for CLART, κ = 0.45, overall agreement = 84% (95% CI:
80–87), and for LA, κ = 0.51, overall agreement 87%
(95% CI: 84–90). Of the 355 HC2-positive samples,








CLART vs. LA (95% CI)







16 121 (30%) 126 (31%) 0.96 (0.78-1.18) 120 (30%) 1 (0%) 6 (1%) 274 (68%) 98% (96-99) 94% (89-98)
18 45 (11%) 53 (13%) 0.85 (0.59-1.23) 45 (11%) 0 (0%) 8 (2%) 348 (87%) 98% (96-99) 85% (72-93)
31 64 (16%) 61 (15%) 1.05 (0.76-1.45) 61 (15%) 3 (1%) 0 (0%) 337 (84%) 99% (98-100) 95% (87-99)
33 42 (10%) 40 (10%) 1.05 (0.70-1.58) 39 (10%) 3 (1%) 1 (0%) 358 (89%) 99% (97-100) 91% (78-97)
35 19 (5%) 16 (4%) 1.19 (0.62-2.28) 16 (4%) 3 (1%) 0 (0%) 382 (95%) 99% (98-100) 84% (60-97)
39 22 (5%) 48 (12%) 0.46 (0.28-0.74) 22 (5%) 0 (0%) 26 (6%) 353 (88%) 94% (91-96) 46% (31-61)
45 16 (4%) 35 (9%) 0.46 (0.26-0.81) 16 (4%) 0 (0%) 19 (5%) 366 (91%) 95% (93-97) 46% (29-63)
51 47 (12%) 50 (12%) 0.94 (0.65-1.37) 46 (11%) 1 (0%) 4 (1%) 350 (87%) 99% (97-100) 90% (79-97)
52 49 (12%) 40 (10%) 1.23 (0.83-1.82) 33 (8%) 16 (4%) 7 (2%) 345 (86%) 94% (92-96) 59% (45-72)
56 30 (7%) 39 (10%) 0.77 (0.49-1.21) 27 (7%) 3 (1%) 12 (3%) 359 (90%) 96% (94-98) 64% (48-78)
58 59 (15%) 40 (10%) 1.48 (1.01-2.15) 38 (9%) 21 (5%) 2 (0%) 340 (85%) 94% (92-96) 62% (49-74)
59 27 (7%) 29 (7%) 0.93 (0.56-1.54) 20 (5%) 7 (2%) 9 (2%) 365 (91%) 96% (94-98) 56% (38-72)
68 25 (6%) 16 (4%) 1.56 (0.85-2.88) 6 (1%) 19 (5%) 10 (2%) 366 (91%) 93% (90-95) 17% (7-34)
Low-risk
6 15 (4%) 13 (3%) 1.15 (0.56-2.39) 12 (3%) 3 (1%) 1 (0%) 385 (96%) 99% (97-100) 75% (48-93)
11 4 (1%) 4 (1%) 1.00 (0.25-3.97) 4 (1%) 0 (0%) 0 (0%) 397 (99%) 100% (99-100) 100% (40-100)
26 3 (1%) 3 (1%) 1.00 (0.20-4.93) 3 (1%) 0 (0%) 0 (0%) 398 (99%) 100% (99-100) 100% (29-100)
40 5 (1%) 6 (1%) 0.83 (0.26-2.71) 5 (1%) 0 (0%) 1 (0%) 395 (99%) 100% (99-100) 83% (36-100)
42 20 (5%) 28 (7%) 0.71 (0.41-1.25) 20 (5%) 0 (0%) 8 (2%) 373 (93%) 98% (96-99) 71% (51-87)
53 50 (12%) 52 (13%) 0.96 (0.67-1.38) 48 (12%) 2 (0%) 4 (1%) 347 (87%) 99% (97-99) 89% (77-96)
54 15 (4%) 36 (9%) 0.42 (0.23-0.75) 14 (3%) 1 (0%) 22 (5%) 364 (91%) 94% (92-96) 38% (22-55)
61 34 (8%) 44 (11%) 0.77 (0.50-1.18) 34 (8%) 0 (0%) 10 (2%) 357 (89%) 98% (95-99) 77% (62-89)
62 12 (3%) 30 (7%) 0.40 (0.21-0.77) 12 (3%) 0 (0%) 18 (4%) 371 (93%) 96% (93-97) 40% (23-59)
66 44 (11%) 40 (10%) 1.10 (0.73-1.65) 37 (9%) 7 (2%) 3 (1%) 354 (88%) 98% (95-99) 79% (64-89)
70 28 (7%) 24 (6%) 1.17 (0.69-1.98) 24 (6%) 4 (1%) 0 (0%) 373 (93%) 99% (97-100) 86% (67-96)
71 1 (0% 2 (0%) 0.50 (0.05-5.49) 0 (0%) 1 (0%) 2 (0%) 398 (99%) 99% (98-100) 0% (0-71)
72 1 (0%) 1 (0%) 1.00 (0.06-15.93) 1 (0%) 0 (0%) 0 (0%) 400 (100%) 100% (99-100) 100% (3-100)
73 11 (3%) 31 (8%) 0.35 (0.18-0.70) 11 (3%) 0 (0%) 20 (5%) 370 (92%) 95% (92-97) 35% (19-55)
81 12 (3%) 14 (3%) 0.86 (0.40-1.83) 12 (3%) 0 (0%) 2 (0%) 387 (97%) 100% (98-100) 86% (57-98)
82 47 (12%) 21 (5%) 2.24 (1.36-3.67) 20 (5%) 27 (7%) 1 (0%) 353 (88%) 93% (90-95) 42% (28-57)
83 15 (4%) 14 (3%) 1.07 (0.52-2.19) 12 (3%) 3 (1%) 2 (0%) 384 (96%) 99% (97-100) 71% (44-90)
84 15 (4%) 26 (6%) 0.58 (0.31-1.07) 15 (4%) 0 (0%) 11 (3%) 375 (94%) 97% (95-99) 58% (37-77)
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CLART detected only low-risk genotypes on 43 (12%),
and no genotypes on 11 (3%). For LA, this was 36 (10%)
and 4 (1%), respectively. Not surprisingly, the agreement
with HC2 was better in women with ≥CIN2.
Detection of cervical lesions
CLART detected 116 of 125 ≥CIN2 (sensitivity: 93%,
95% CI: 87–97), and 84 of 90 ≥CIN3 (sensitivity: 93%,
95% CI: 86–98; Table 7). LA detected 120 ≥CIN2 (sensi-
tivity: 96%, 95% CI: 91–99) and 87 ≥CIN3 (sensitivity:
97%, 95% CI: 91–99). HC2 detected 123 ≥CIN2 and
89 ≥CIN3, sensitivity 98% (95% CI: 94–100), and 99%
(95% CI: 94–100), respectively. These differences, assessed
through relative sensitivity (Table 7), were not statistically
significant. Three women with cervical cancer tested posi-
tive for high-risk HPV on all three assays. The fourth
woman tested negative on CLART, and positive on LA
(genotype 39) and HC2. Given that all women had cyto-
logical abnormalities, the specificity of all three assays was
low, but significantly higher (assessed through relative
specificity) for CLART (30%, 95% CI: 25–36, for ≥CIN2)
and LA (26%, 95% CI: 21–32) than for HC2 (17%, 95% CI:
12–22).
Discussion
In Danish women with abnormal cytology, CLART and
LA were highly comparable for detection of HPV geno-
types 16, 18, 31, 33, 35, and 51. Furthermore, “substan-
tial” agreement was observed for HPV 39, 45, 52, 56, 58,
and 59, which translated into ~50-60% of cases mutually
detected by the two assays. Finally, the agreement was
poor for HPV 68, present in <1% of cervical cancers [5].
There were no statistically significant differences in
detecting high-risk HPV infections overall, and the two
assays detected similar numbers of high-grade CIN. For
low-risk genotypes, the differences were somewhat more
pronounced, but still generally acceptable, although for
genotypes HPV 54, 62, 71, 73, and 82 the agreement was
poor. The agreement in detecting HPV infections with
HC2, a thoroughly validated clinical screening assay
[18], was moderate for both CLART and LA, but with
no statistically significant differences in detecting high-
grade CIN.
CLART was previously compared to LA using Thin-
Prep samples. Using 538 samples from women in oppor-
tunistic examination, Chranioti and colleagues found
high levels of agreement in detecting the 13 high-risk
HPV genotypes [19]. HPV 68 was though detected in
only two samples, in which it was detected by both as-
says. Analytical performance of CLART and LA was re-
ported as part of the WHO HPV LabNet Proficiency
Studies [4,11,20]. In the most recent published evalu-
ation [4], both assays had high analytical sensitivity for









CLART vs. LA (95% CI)






16 55 (44%) 57 (46%) 0.96 (0.73-1.27) 55 (44%) 0 (0%) 2 (2%) 68 (54%) 98% (94-100) 96% (88-100)
18 18 (14%) 18 (14%) 1.00 (0.55-1.83) 18 (14%) 0 (0%) 0 (0%) 107 (86%) 100% (97-100) 100% (81-100)
31 30 (24%) 30 (24%) 1.00 (0.64-1.55) 30 (24%) 0 (0%) 0 (0%) 95 (76%) 100% (97-100) 100% (88-100)
33 21 (17%) 22 (18%) 0.95 (0.55-1.64) 21 (17%) 0 (0%) 1 (1%) 103 (82%) 99% (96-100) 95% (77-100)
35 7 (6%) 6 (5%) 1.17 (0.40-3.37) 6 (5%) 1 (1%) 0 (0%) 118 (94%) 99% (96-100) 86% (42-100)
39 4 (3%) 12 (10%) 0.33 (0.11-1.01) 4 (3%) 0 (0%) 8 (6%) 113 (90%) 94% (88-97) 33% (10-65)
45 6 (5%) 17 (14%) 0.35 (0.14-0.87) 6 (5%) 0 (0%) 11 (9%) 108 (86%) 91% (85-96) 35% (14-62)
51 15 (12%) 17 (14%) 0.88 (0.46-1.69) 15 (12%) 0 (0%) 2 (2%) 108 (86%) 98% (94-100) 88% (64-99)
52 17 (14%) 15 (12%) 1.13 (0.59-2.17) 11 (9%) 6 (5%) 4 (3%) 104 (83%) 92% (86-96) 52% (30-74)
56 6 (5%) 9 (7%) 0.67 (0.24-1.82) 5 (4%) 1 (1%) 4 (3%) 115 (92%) 96% (91-99) 50% (19-81)
58 19 (15%) 10 (8%) 1.90 (0.92-3.92) 10 (8%) 9 (7%) 0 (0%) 106 (85%) 93% (87-97) 53% (29-76)
59 9 (7%) 10 (8%) 0.90 (0.38-2.14) 8 (6%) 1 (1%) 2 (2%) 114 (91%) 98% (93-100) 73% (39-94)
68 7 (6%) 3 (2%) 2.33 (0.62-8.82) 0 (0%) 7 (6%) 3 (2%) 115 (92%) 92% (86-96) 0% (0-31)
Table 4 Agreement between CLART and LA with respect









Single infection 89 19 13 121 (30%)
Multiple infection 40 216 3 259 (65%)
No HPV genotypea 1 0 20 21 (5%)
Total 130 (32%) 235 (59%) 36 (9%) 401 (100%)
aOr genotypes not detectable by both CLART and LA (CLART: 43, 44, 85, 89;
LA: 55, 64, 67, 69, IS39, CP6108).
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HPV 16 and 18, even at low plasmid concentration
levels (5–50 international units/genomic equivalent).
CLART more often correctly detected HPV 6, 11, 31, 33,
35, 51, 52, 58, 59, and 66 than LA, although the number
of compared datasets was small. The opposite was ob-
served for HPV 45, 56 and 68b, which were compared at
high concentration levels (500 international units/gen-
omic equivalent). Moreover, WHO LabNet panel data
from 2011 showed similar performance in genotype de-
tection between CLART and PapilloCheck [4]. Data
from the most recent 2013 WHO global proficiency
panel are awaited.
Pista and colleagues compared CLART to HC2 in
women attending primary and gynecologic outpatient
clinics, and found the same sensitivity for ≥CIN2, 96%,
with similar specificities (74% vs. 71%) [14]. In a study of
women referred for colposcopy reported by Szarewski
and colleagues, the sensitivity of LA for ≥CIN2 was 98%,
and that of HC2 100%. CLART did not perform opti-
mally owing to “technical problems during the evalu-
ation”, with sensitivity for ≥CIN2 of only 81%. However,
it should be noted that the study used an earlier version
of the CLART assay. Furthermore, the accuracy of HPV
test results using genotyping assays may improve with a
laboratory’s experience with a particular assay, and dif-
ferences between laboratories can be substantial [4].
Our study is the first comparison of genotype detec-
tion and clinical performance of CLART and LA using
SurePath samples. It is also one of the first reports on
LA with SurePath in general. Previously, Chernesky and
colleagues studied 133 routine samples and found a 94%
overall agreement in detecting high-risk HPV infections
between LA and HC2, with κ = 0.86 [21]. This was sub-
stantially higher than in our study; however, the samples
in the study by Chernesky and colleagues were tested in
two laboratories, and the distribution of cytological ab-
normalities, an important determinant of agreement be-
tween HPV assays [15] was not reported.
One of the strengths of this study was the use of fresh,
routine SurePath cytology samples from a large Danish
cervical screening laboratory with well-established cy-
tology performance. The genotyping assays were com-
pared on equal terms: all testing was undertaken in the
same laboratory by the same staff; samples were proc-
essed manually, and the analysis was limited to the 31
HPV genotypes that are detectable by both assays. Each
LA hybridization strip was read by two experienced staff
members, and discrepancies were resolved by consensus.
Histological diagnoses were available for 86% of the
women, with only 4% lost to follow-up.
Interpretation of the detection of genotypes with weak
signals on both CLART and LA might be considered a
weakness of our study in the sense that other laborator-
ies may have opted for different approaches. Our current
clinical standard operating procedure calls for weak sig-
nals (below cut off, but visible) to be considered positive
if the weak signal is detected along with other genotypes
detected above the cut off. This approach was though
not playing a major role in our data; after including ge-
notypes with weak signals, the test results changed from
low-risk to high-risk positive in 7 samples for CLART,
and 5 for LA, with 1 and 0 ≥CIN2, respectively. This
low number of ≥CIN2 was consistent with previous ob-
servations of low numbers of CIN lesions found close to
manufacturer-determined cut-offs for other HPV assays
[22]. The LA and CLART package inserts do not provide
information on how to interpret genotype findings with
weak signals, leaving it up to the individual laboratory to
Table 6 CLART and LA: agreement with HC2
Genotyping assay Assay+/HC2+ Assay+/HC2- Assay-/HC2+ Assay-/HC2-
401 women with abnormal cytology
CLART 301 (75%) 10 (2%) 54 (13%) 36 (9%)
LA 315 (79%) 11 (3%) 40 (10%) 35 (9%)
125 women with ≥ CIN2
CLART 116 (93%) 0 (0%) 7 (6%) 2 (2%)
LA 120 (96%) 0 (0%) 3 (2%) 2 (2%)
Table 5 Agreement between CLART and LA in 401 women with abnormal cytology
LA CLART Total
High-risk genotypes Low-risk genotypes No genotypesa
High-risk genotypes 306 12 8 326 (81%)
Low-risk genotypes 5 41 8 54 (13%)
No genotypesa 0 1 20 21 (5%)
Total 311 (78%) 54 (13%) 36 (9%) 401 (100%)
aOr genotypes not detectable by both CLART and LA (CLART: 43, 44, 85, 89; LA: 55, 64, 67, 69, IS39, CP6108).
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establish their own interpretation algorithms. Our ap-
proach is justified by the fact that individual genotypes
appear more difficult to detect in co-infections, as com-
pared to single infections [4], owing to the dynamics of
multiplex PCR reactions. In particular, HPV genotypes
with high viral loads may through primer or reagent
competition lessen the PCR amplification of other truly
present genotypes in a sample. This issue and its conse-
quences for the clinical management have been little dis-
cussed in the literature.
For use of any HPV assay in cervical screening, quality
control and quality assurance aspects should also be
considered. In this respect, sample identification is not
provided for the individual LA strips, whereas CLART’s
software stores sample-specific identification informa-
tion printed on the individual array by the manufacturer,
which is reported alongside the testing results from the
automated reader. Hence, CLART has a state-of-the-art
chain of custody and is not prone to inter-observer vari-
ability given the automated read-out.
Conclusions
In our referral population, CLART was comparable to
LA in terms of analytical and clinical performance, and
CLART’s clinical sensitivity was comparable to that of
HC2, whereas its specificity was higher. In the absence
of an internationally recognized genotyping gold stand-
ard, CLART HPV2 appears to be a good candidate for
genotyping HPV infections in clinical settings where
high throughput and chain of custody is required.
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